vadadustat   Click here for help

GtoPdb Ligand ID: 11831

Synonyms: AKB-6548 | AKB6548 | Vafseo®
Approved drug PDB Ligand
vadadustat is an approved drug (Japan (2020), EMA (2023), FDA (2024))
Compound class: Synthetic organic
Comment: Vadadustat is an orally bioavailable HIF prolyl-hydroxylase inhibitor. It targets the enzymes PHD1, PHD2 and PHD3 to mediate an increase in endogenous erythropoietin production which delivers anti-anemia action. See also enarodustat.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 99.52
Molecular weight 306.04
XLogP 0.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)CNC(=O)c1ncc(cc1O)c1cccc(c1)Cl
Isomeric SMILES c1cc(cc(c1)Cl)c1cc(c(nc1)C(=O)NCC(=O)O)O
InChI InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
InChI Key JGRXMPYUTJLTKT-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
First international approval of vadadustat was issued in Japan (in 2020) as a treatment for anaemia associated with chronic kidney disease [3]. It was later approved by the EMA (2023) and FDA (2024) for the same indication.